JPWO2020198531A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020198531A5 JPWO2020198531A5 JP2021557377A JP2021557377A JPWO2020198531A5 JP WO2020198531 A5 JPWO2020198531 A5 JP WO2020198531A5 JP 2021557377 A JP2021557377 A JP 2021557377A JP 2021557377 A JP2021557377 A JP 2021557377A JP WO2020198531 A5 JPWO2020198531 A5 JP WO2020198531A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- cancer
- chimeric antigen
- intracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025024834A JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824080P | 2019-03-26 | 2019-03-26 | |
| US62/824,080 | 2019-03-26 | ||
| US201962931103P | 2019-11-05 | 2019-11-05 | |
| US62/931,103 | 2019-11-05 | ||
| US202062969569P | 2020-02-03 | 2020-02-03 | |
| US62/969,569 | 2020-02-03 | ||
| PCT/US2020/025069 WO2020198531A2 (en) | 2019-03-26 | 2020-03-26 | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024834A Division JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527081A JP2022527081A (ja) | 2022-05-30 |
| JP2022527081A5 JP2022527081A5 (https=) | 2023-04-03 |
| JPWO2020198531A5 true JPWO2020198531A5 (https=) | 2023-04-03 |
Family
ID=72610137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557377A Pending JP2022527081A (ja) | 2019-03-26 | 2020-03-26 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
| JP2025024834A Pending JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024834A Pending JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230312708A1 (https=) |
| EP (1) | EP3953372A4 (https=) |
| JP (2) | JP2022527081A (https=) |
| KR (1) | KR20210143804A (https=) |
| CN (1) | CN113710688A (https=) |
| AU (1) | AU2020248448B2 (https=) |
| CA (1) | CA3134465A1 (https=) |
| IL (1) | IL286618A (https=) |
| MX (1) | MX2021011494A (https=) |
| SG (1) | SG11202110131SA (https=) |
| WO (1) | WO2020198531A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240415883A1 (en) * | 2021-02-01 | 2024-12-19 | The Regents Of The University Of California | Treatment of neuroendocrine cancers |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2023217227A1 (zh) | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| US12600801B2 (en) * | 2022-07-11 | 2026-04-14 | Fred Hutchinson Cancer Center | Single-domain antibodies that bind ROR1 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| KR20250052305A (ko) * | 2023-10-10 | 2025-04-18 | 서울대학교산학협력단 | 키메라 항원 수용체를 발현하는 자연 살해 세포를 이용한 종양 미세환경의 주피세포를 표적하는 항암 세포 치료 기법 및 치료 효능 평가를 위한 종양 미세환경 오가노이드 모델 제작 기술 |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| KR102048855B1 (ko) * | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| AU2015343013B2 (en) * | 2014-11-05 | 2020-07-16 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| JP6865688B2 (ja) * | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| KR20190003938A (ko) * | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| EP3523331A1 (en) * | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| CN108424458A (zh) * | 2017-02-13 | 2018-08-21 | 上海恒润达生生物科技有限公司 | 靶向ny-eso-1的嵌合抗原受体及其用途 |
| MX2019015057A (es) * | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| BR112022009611A2 (pt) * | 2019-11-18 | 2022-08-09 | Univ California | Anticorpos anti-ror-2 e métodos de uso |
-
2020
- 2020-03-26 EP EP20778519.7A patent/EP3953372A4/en active Pending
- 2020-03-26 SG SG11202110131SA patent/SG11202110131SA/en unknown
- 2020-03-26 CA CA3134465A patent/CA3134465A1/en active Pending
- 2020-03-26 MX MX2021011494A patent/MX2021011494A/es unknown
- 2020-03-26 WO PCT/US2020/025069 patent/WO2020198531A2/en not_active Ceased
- 2020-03-26 CN CN202080028702.4A patent/CN113710688A/zh active Pending
- 2020-03-26 AU AU2020248448A patent/AU2020248448B2/en active Active
- 2020-03-26 JP JP2021557377A patent/JP2022527081A/ja active Pending
- 2020-03-26 KR KR1020217032699A patent/KR20210143804A/ko not_active Ceased
- 2020-03-26 US US17/598,200 patent/US20230312708A1/en active Pending
-
2021
- 2021-09-23 IL IL286618A patent/IL286618A/en unknown
-
2025
- 2025-02-19 JP JP2025024834A patent/JP2025081512A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025081512A5 (https=) | ||
| Wahl et al. | The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease | |
| Chu et al. | Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells | |
| AU2015308499B2 (en) | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP7590034B2 (ja) | Ｎｋｇ２ａを標的にする抗体及びその使用 | |
| JP2022031784A5 (https=) | ||
| KR20210021347A (ko) | 다양한 다중 항원의 표적화를 위한 역방향 범용 키메라 항원 수용체 발현 면역 세포, 이의 제조 방법 및 암, 감염증 및 자가면역 장애의 치료를 위한 이의 용도 | |
| CN113234682A (zh) | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 | |
| JPWO2020160050A5 (https=) | ||
| CN108884164A (zh) | 用于免疫疗法的经修饰细胞 | |
| US11945878B2 (en) | Switch molecule and switchable chimeric antigen receptor | |
| Schlereth et al. | Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3 | |
| JP2024512382A (ja) | Ｐｄ－１標的化ｉｌ－２バリアント免疫コンジュゲートと抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体の併用療法 | |
| JPWO2020198531A5 (https=) | ||
| CA3240254A1 (en) | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors | |
| A Baeuerle et al. | Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer | |
| JPWO2020092467A5 (https=) | ||
| JP7619682B2 (ja) | Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| US20240101701A1 (en) | Antibody-derived t cell activating technologies | |
| WO2023155852A1 (zh) | 经修饰的免疫效应细胞及其用途 | |
| JPWO2021102055A5 (https=) | ||
| Holzinger et al. | CARs on the highway: chimeric antigen receptor modified T cells for the adoptive cell therapy of malignant diseases | |
| JPWO2020172440A5 (https=) | ||
| US20250250316A1 (en) | Design and composition of huanti-cd19 chimeric antigen receptor targeting b-cell malignancies thereof | |
| Burns | The Major Clinical Components of Cancer Immunotherapy (Modulating Cell-Mediated Immune Mechanisms) |